HRGN - Earnings call 3 2023 | Harvard Apparatus Regenerative Technology, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Harvard Apparatus Regenerative Technology Q3 2023 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Joe Damasio, Chief Financial Officer. Thank you, sir.

You may begin.

Joseph Damasio

right. All everyone. morning, Good Damasio, Officer. Joe Chief is Financial This

On our Chairman with me Jerry He, today is and the call Chief Executive Officer.

it statements. today, turn the that I over let statements. Jerry, Before me constitute company's forward-looking forward-looking will In we discussion our make statements to review

projected our detailed for results previously and in XX, public report Form performance XX-K our year we and and ended XXXX, risks actual differ materially annual to Our what filings. uncertainties, the December from other may have due including those on

Any forward-looking related relied at those should of including and estimates activities, to date. be results statements, today our represent upon not as our subsequent future as representing our estimates any and

press financial presented Presentations. and statistical information archived material, section which available in in any the is our or & will in Events release, website under Investors be call, Additionally, our of the not included

Now it I will turn to Jerry. over

Junli He

conference discuss Thank this to Harvard quarter you, matters. for related to Welcome, Joe. and call Regen everyone, earnings

had a during Regen the Harvard XXXX. of number has quarter third developments of

approval approval the is activated site regulatory the screening Application European second for the by the are Orphan of medicines new the review Agency with Disease We of product, or currently Implant, patients. Esophageal the and for It's that Medicines University the we Cellspan agency EMA. European our centralized trial Union. and for in lead an the First clinical Michigan

CEI for an of initiation marked for our Cellspan The short, first or clinical milestone Implant, Regen. for Esophageal important Harvard study

our possible. clinics bringing to our forward further understanding testing benefit as for the organic look tubular have we to the and Our soon platform patients patients potential numerous the regeneration. in preclinical technology as treatment as of demonstrated effective an for studies CEI We as

which consumers targeted XX,XXX or the company's supplements, USD sales. In the e-commerce medicine Kong, longevity in sales. Limited, business are Harvard products will its China in the subsidiary initially through Apparatus Greater range The LTD., These a products include the of to on quarter complements marketed Asia, product at launched longevity business. generating Technology in our business in online and broad longevity dietary Regenerative of focused product HRGN Hong third or region regenerative XXXX, public general

The is additional generate China flow revenue way distracting longevity operating States. and efforts a United great our product business to in from and R&D clinical trial without the cash

turn call review the will the please. to Joe, I to QX. Now financials Joe over for

Joseph Damasio

our Sure. I want of to results. cover briefly third financial highlights the quarter

to or the September months per share X X XXXX, compared loss ended the September share of $X.X or for net million $X.XX ended reported a For months $X.X the a of company per net million XX, loss $X.XX and loss 'XX from year-over-year million The XXXX. of net the in expense share-based the count-related increased compensation million. awards of costs increase third head $X.X XX, approximately $X.X quarter of vesting due to million time-based of $X.X was

September XXXX, approximately in cash during $X.X cash, We XX, hand ended short-term had XX, and $X.X [ equivalents and September cash we At million debt. no XXXX. the X $X.X on million used (sic) ] operations had for months million investments of

from As first that current back Jerry. and capital our expect aggregate Based XXXX, plan back to this sufficient of a it requirements to which XX, pass of expenses cash given $X operating -- to of and expenditure be infusion, approximately placement cash quarter XXXX. fund on on operating September we million consideration in April the our our current proceeds XXXX. I'll will closed through we received private

Junli He

floor any for the Now questions. we open will

Operator

no that this appears It Instructions] there questions time. [Operator at are

would closing like Jerry I the for to floor now turn He over to back comments.

Junli He

Thank you We product look possible. soon to you. Regenerative again our as the forward to Also for much time. joining Technology making market very Thank next today. see as you call Harvard

Operator

This concludes today's teleconference.

you Thank time. You may your participation. at disconnect lines this for your

Harvard Apparatus Regenerative Technology (HRGN) 13 Nov 232023 Q3 Earnings call transcript